VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a definitive agreement with C3 Global Biosciences™ (C3GBS), a cause-driven organization committed to developing sustainable health solutions through the advancement of cannabis science.
This news is in connection with Isodiol’s previous announcement affirming that the Company had entered into a binding agreement with C3GBS. The official press release can be viewed here.
“At Isodiol, we believe that the ideation, creation, and evaluation of new ideas, is an interconnected process that drives innovation forward,” said Marcos Agramont, CEO of Isodiol. “C3GBS’s world-class team has a clear mission, focused strategy and healthy culture – all of which we expect will support the creation of value over the long term for Isodiol, our shareholders, and society.”
C3GBS’ strategy involves using science and technology-based innovation to deliver better patient outcomes in areas of healthcare with the utmost need. With C3GBS, Isodiol seeks to develop and advance proprietary, pharmaceutical-grade CBD Bioactive products that can produce positive real-world outcomes for patients and healthcare providers.
“C3GBS is an expert in conducting research, turning insights into tangible products, and incorporating those products into treatment programs, which are then evaluated with academic rigor,” said Agramont. “They are well-prepared for a world with both a growing and aging population that has evolving healthcare needs.”
The Company will issue C3GBS $826,522.45 USD in stock, subject to a 36-month escrow.
For more information on Isodiol, please visit www.isodiol.com
For more information on C3GBS, please visit www.c3globalbiosciences.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
North 6th Agency
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.